title: The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas.
abstract: OBJECTIVE
  The selective suppression phenomenon of the cytotoxic immune response may be brought about by an increase in sRCAS1 serum concentration during the progression of cancer.
  
  
  METHODS
  We studied sRCAS1 serum concentration levels in patients with adenocarcinomas and squamous cell carcinomas. The healthy control consisted of patients who were in the mid-proliferative or mid-secretory phases of their cycles.
  
  
  RESULTS
  Statistically, significantly higher sRCAS1 blood serum concentration levels were found in patients experiencing a recurrence of cancer in comparison to those patients who had undergone radical surgical treatment. For patients in the early stages of cancer, sRCAS1 blood serum concentration levels were statistically, significantly higher than those found in patients who were in the proliferative cycle phase and who were comparable to the levels found in patients in the secretory cycle phase.
  
  
  CONCLUSIONS
  The blood serum concentration level of RCAS1 seems to determine the level of immune system activity restriction that accompanies all three processes-decidualization, cancer development, and cancer relapse.
authors.affiliation: Department of ENT, Head and Neck Surgery of the Jagiellonian University, Krakow, Poland.
authors.forename: Magda
authors.initials: M
authors.lastname: Dutsch-Wicherek
authors.forename: Lukasz
authors.initials: L
authors.lastname: Wicherek
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000276:immunology* / Q000628:therapy; D000328:Adult; D000951:Antigens, Neoplasm / Q000097:blood* / Q000276:immunology*; D001943:Breast Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy; D002294:Carcinoma, Squamous Cell / Q000097:blood / Q000276:immunology* / Q000628:therapy; D003602:Cytotoxicity, Immunologic; D005260:Female; D006801:Humans; D007108:Immune Tolerance; D008597:Menstrual Cycle / Q000097:blood / Q000276:immunology*; D009364:Neoplasm Recurrence, Local / Q000097:blood / Q000276:immunology; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy; D011247:Pregnancy; D019139:Tumor Escape; D014594:Uterine Neoplasms / Q000097:blood / Q000276:immunology* / Q000628:therapy
chemical_list: D000951:Antigens, Neoplasm; C120762:EBAG9 protein, human